News Sharing
For sharing news, please enter the email address of you and the receiver, then press SEND button.*Mandatory Fields
Receiver*
Enter email addresses, separated by semicolon (;). E.g. a@a.com;b@b.com
Your email address*
 Content Sharing
<Research>Citi Initiates 90-Day Positive Catalyst Watch on PHARMARON w/ Rating Buy
Citi has published a research report initiating a 90-day positive catalyst watch on PHARMARON (03759.HK). The primary catalysts include the group's upcoming announcement of las...
Reset
Send
The window will close in 5 seconds
<Research>Citi Initiates 90-Day Positive Catalyst Watch on PHARMARON w/ Rating Buy
Close
Recommend
4
Positive
2
Negative
2
 
SHORT SELL
 
STOCK INFO
aacat by AASTOCKS
Open a new trading account to get NVDA share!

Citi has published a research report initiating a 90-day positive catalyst watch on PHARMARON (03759.HK)  +0.100 (+0.479%)    Short selling $4.57M; Ratio 5.120%   . The primary catalysts include the group's upcoming announcement of last year's full-year results and accelerated order growth, leading to more optimistic guidance for this year.

The broker has given PHARMARON a Buy rating and a target price of HKD45, considering it as a global leader in drug research and development, benefiting from the growth trend of China's CRO industry. While maintaining its leadership in drug research and development, PHARMARON is also expanding into downstream late-stage clinical development and commercial production, as well as venturing into the biopharmaceutical field.
(HK stocks quote is delayed for at least 15 mins.Short Selling Data as at 2026-04-02 16:25.)

Related NewsKanglong Chemical (03759.HK) Rises Over 8% at Midday as Nomura Raises Target Price

AASTOCKS Financial News
Copyright(C) AASTOCKS.com Limited 2000. All rights reserved.
Disclaimer: AASTOCKS.com Ltd, HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the Information provided but do not guarantee its accuracy or reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.